# 5Y Capital

> 5Y Capital is a VC fund in Central backing Health Care and Biotechnology. See 36 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Central, Hong Kong
- Total investments: 36
- Last investment: Sep 2023
- Lead investor: 50%
- Last updated: Aug 2026

5Y Capital is a VC fund in Central focused on Health Care and Biotechnology. Morningside Ventures is an investment firm

## Contacts

5 contacts available for 5Y Capital. Shizune tracks 2 team members at 5Y Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/morningside-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 22 | 61% |
| Biotechnology | 14 | 39% |
| Medical | 7 | 19% |
| Medical Device | 7 | 19% |
| Health Diagnostics | 7 | 19% |

42 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 14 | 39% |
| Series A | 8 | 22% |
| Series C | 6 | 17% |
| Seed | 3 | 8% |
| Series D | 1 | 3% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 19 | 53% |
| China | 6 | 17% |
| United Kingdom | 5 | 14% |
| Spain | 1 | 3% |
| Singapore | 1 | 3% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Gerald Chan | Founder | 0 | https://shizune.co/investors/profile/gerald-chan-8413 |
| Greg Weaver | CFO Consulting | 0 | https://shizune.co/investors/profile/greg-weaver-7ce4 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AdaptX | AdaptX (formerly MDmetrix) is a healthcare data analytics, visualization, and AI company that serves hospitals and surgery centers. By empowering medical leaders and frontline clinicians to access, analyze, and improve clinical and workflow outcomes, AdaptX enables providers to improve care and lower costs, transforming clinical operations. Foundedin Seattle in 2016, AdaptX was spun out of Seattle Children's Hospital. | $10M | Series B | Sep 11, 2023 |  |
| Cyted | Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather thantreated. | $16.7M | Series A | May 17, 2023 |  |
| Wangli Technology | Wangli Technology is a digital therapy technology platform for mental illness focusing on exploring the field of human brain and spirit. | $14.4M | Venture - Series Unknown | Dec 05, 2022 |  |
| New Amsterdam Pharma | NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. | $235M | Post-IPO Equity | Nov 23, 2022 |  |
| PsycApps | Award-winning eQuoo, the evidence-based Emotional Fitness Game, combines the excitement and joy of the gaming industry and the expertise of mental health professionals to provide a new form of mobile prevention and therapy. The game is designed for young adults aged 18-28 and is backed by academic research led by Psychologist Silja Litvin. eQuoousers are five times more engaged than average mental health app users, making the game a pioneer in sustainable and scalable mobile therapy. eQuoo was successfully tested in a 5-week, 3-arm randomized controlled trial, proving that it significantly boosts resilience, interpersonal relationship skills, personal growth and lowers anxiety. The game scores 85% with ORCHA and is being accepted into the NHS App Library.The company behind eQuoo is backed by Techstars, and has partnered with many charities, including Mental Health America and has caught the attention of major news outlets like Forbes and TechCrunch. They are gearing up to conduct the biggest clinical trial around a mental health app in the UK with UCL and 45k students in September testing for depression and anxiety. | $1.7M | Seed | Sep 01, 2022 |  |
| Suvera | At Suvera we superpower primary care to deliver truly effective virtual care for patients with long-term conditions. Effective for us means improved outcomes for patients - less hospital admissions, less doctor appointments, more time in good health. | $6.1M | Seed | Jul 28, 2022 |  |
| SimpliFed | SimpliFed is a healthcare technology company that provides virtual maternal care focused on breastfeeding and baby feeding support for families. It offers a telehealth platform that connects parents with certified lactation and baby-feeding specialists, delivering personalized, evidence-based care from pregnancy through the postpartum period. Theplatform includes services such as feeding guidance, remote monitoring, mental health screenings, and ongoing support to improve maternal and infant health outcomes. SimpliFed works closely with healthcare providers and health plans, integrating its services into existing care systems to enhance access and continuity of care. Its approach emphasizes inclusive, judgment-free support, helping parents make informed decisions about feeding methods while addressing both physical and emotional well-being. | $6M | Seed | May 10, 2022 |  |
| Apnimed | Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has seriousconsequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles.Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions.Apnimed, Inc. was founded in 2017 and is located in Cambridge, Massachusetts. | $62.5M | Series C | May 04, 2022 |  |
| Igenesis | Igenesis is a biotechnology company that provides molecular diagnostic technologies. | $15.8M | Series C | Mar 08, 2022 |  |
| Curve Health | Curve Health is senior care without walls. It is a platform that's reduced patient transfers from Skilled Nursing Facilities (SNFs) to Emergency Departments by 50%+, Curve advances connected senior care by bridging the silos that hinder healthcare delivery today; enabling physicians to remotely care for patients in SNFs, at home, in ambulancesor wherever they may be. Curve combines telemedicine, a health information exchange, predictive analytics, and smart billing into a single platform, resulting in higher quality care + significant return on investment while ensuring the most seamless patient experience. | $12M | Series A | Feb 06, 2022 |  |

10 of 36 investments shown.

## Co-investors
- [Morningside](https://shizune.co/investors/profile/morningside-technology-ventures) — VC Fund, 17 deals together
- [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures) — VC Fund, 3 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 3 deals together
- [Alida Capital International](https://shizune.co/investors/profile/alida-capital-international) — VC Fund, 2 deals together
- [Hongtai Capital Holdings](https://shizune.co/investors/profile/aplus-capital) — VC Fund, 2 deals together
- [Benslie Investment Group](https://shizune.co/investors/profile/benslie-international-ltd) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [Medical Device VC Funds in Spain](https://shizune.co/investors/medical-device-vc-funds-spain)

## FAQ

### What does 5Y Capital invest in?

5Y Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series A stage. Most of the 36 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact 5Y Capital?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at 5Y Capital?

The team at 5Y Capital includes Gerald Chan (Founder) and Greg Weaver (CFO Consulting). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co